Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,375 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,977 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05401214 | Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination) | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 13, 2025 | clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 |
| clinicaltrials |
| NCT04809584 | 18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer | approved for marketing | — | — | Stanford UniversityOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT04452136 | Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer | approved for marketing | — | — | Jeanne LinkOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04348682 | Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging | approved for marketing | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT04377152 | Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01606982 | Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Feb 17, 2017 | clinicaltrials |
| NCT02355054 | Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study | approved for marketing | — | — | Washington University School of MedicineOTHER | 1 | Jan 20, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jun 13, 2025source: clinicaltrials